These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16961676)

  • 1. Evaluation of a primary care-oriented brief counselling intervention for obesity with and without orlistat.
    Poston WS; Haddock CK; Pinkston MM; Pace P; Reeves RS; Karakoc N; Jones P; Foreyt JP
    J Intern Med; 2006 Oct; 260(4):388-98. PubMed ID: 16961676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification.
    Poston WS; Reeves RS; Haddock CK; Stormer S; Balasubramanyam A; Satterwhite O; Taylor JE; Foreyt JP
    Int J Obes Relat Metab Disord; 2003 Dec; 27(12):1486-93. PubMed ID: 14634679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
    Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orlistat in the long-term treatment of obesity in primary care settings.
    Hauptman J; Lucas C; Boldrin MN; Collins H; Segal KR
    Arch Fam Med; 2000 Feb; 9(2):160-7. PubMed ID: 10693734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of orlistat on cardiovascular disease risk in obese adults.
    Swinburn BA; Carey D; Hills AP; Hooper M; Marks S; Proietto J; Strauss BJ; Sullivan D; Welborn TA; Caterson ID
    Diabetes Obes Metab; 2005 May; 7(3):254-62. PubMed ID: 15811142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial.
    Chanoine JP; Hampl S; Jensen C; Boldrin M; Hauptman J
    JAMA; 2005 Jun; 293(23):2873-83. PubMed ID: 15956632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines.
    Rissanen A; Lean M; Rössner S; Segal KR; Sjöström L
    Int J Obes Relat Metab Disord; 2003 Jan; 27(1):103-9. PubMed ID: 12532161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity.
    Krempf M; Louvet JP; Allanic H; Miloradovich T; Joubert JM; Attali JR
    Int J Obes Relat Metab Disord; 2003 May; 27(5):591-7. PubMed ID: 12704403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of orlistat 60 mg on weight loss and body fat mass in US Army soldiers.
    Smith TJ; Crombie A; Sanders LF; Sigrist LD; Bathalon GP; McGraw S; Young AJ
    J Acad Nutr Diet; 2012 Apr; 112(4):533-40. PubMed ID: 22717217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A primary care intervention for weight loss: results of a randomized controlled pilot study.
    Tsai AG; Wadden TA; Rogers MA; Day SC; Moore RH; Islam BJ
    Obesity (Silver Spring); 2010 Aug; 18(8):1614-8. PubMed ID: 20019680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of orlistat initiation on cardiovascular treatment use: a 6-year population-based cohort study.
    Czernichow S; Knol MJ; Fezeu L; Grobbee DE
    Eur J Prev Cardiol; 2012 Jun; 19(3):484-9. PubMed ID: 21464100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects.
    Madsen EL; Bruun JM; Skogstrand K; Hougaard DM; Christiansen T; Richelsen B
    Metabolism; 2009 Jul; 58(7):946-53. PubMed ID: 19409578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
    Muls E; Kolanowski J; Scheen A; Van Gaal L;
    Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonsurgical weight loss for extreme obesity in primary care settings: results of the Louisiana Obese Subjects Study.
    Ryan DH; Johnson WD; Myers VH; Prather TL; McGlone MM; Rood J; Brantley PJ; Bray GA; Gupta AK; Broussard AP; Barootes BG; Elkins BL; Gaudin DE; Savory RL; Brock RD; Datz G; Pothakamuri SR; McKnight GT; Stenlof K; Sjöström LV
    Arch Intern Med; 2010 Jan; 170(2):146-54. PubMed ID: 20101009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.
    Wadden TA; Berkowitz RI; Womble LG; Sarwer DB; Arnold ME; Steinberg CM
    Obes Res; 2000 Sep; 8(6):431-7. PubMed ID: 11011909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive lifestyle intervention combined with the choice of pharmacotherapy improves weight loss and cardiac risk factors in the obese.
    Frost G; Lyons F; Bovill-Taylor C; Carter L; Stuttard J; Dornhorst A
    J Hum Nutr Diet; 2002 Aug; 15(4):287-95; quiz 297-9. PubMed ID: 12153502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up.
    MacLaughlin HL; Cook SA; Kariyawasam D; Roseke M; van Niekerk M; Macdougall IC
    Am J Kidney Dis; 2010 Jan; 55(1):69-76. PubMed ID: 19926371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
    Richelsen B; Tonstad S; Rössner S; Toubro S; Niskanen L; Madsbad S; Mustajoki P; Rissanen A
    Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.